Identification of a neurovascular signaling pathway regulating seizures in mice

Annals of Clinical and Translational Neurology

Volumn 2, Issue 7, 2015, Pages 722-738

  Fredriksson, Linda ^a,b   Stevenson, Tamara K ^b   Su, Enming J ^b   Ragsdale, Margaret ^b   Moore, Shannon ^b   Craciun, Stefan ^b   Schielke, Gerald P ^b   Murphy, Geoffrey G ^b   Lawrence, Daniel A ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; IMATINIB; KAINIC ACID; MANNITOL; NEUROSERPIN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; RINGER LACTATE SOLUTION; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DISEASE COURSE; ELECTROENCEPHALOGRAPHY; ELECTROPHYSIOLOGY; GENETICALLY ENGINEERED MOUSE STRAIN; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MEDICAL DECISION MAKING; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEIZURE; SIGNAL TRANSDUCTION; WILD TYPE MOUSE;

EID: 84944447033     PISSN: None     EISSN: 23289503     Source Type: Journal    
DOI: 10.1002/acn3.209     Document Type: Article

References (76)

1. Lemarchant S, Docagne F, Emery E, et al. tPA in the injured central nervous system: different scenarios starring the same actor? Neuropharmacology 2012;62:749–756.
2. Su EJ, Fredriksson L, Schielke GP, et al. Tissue plasminogen activator-mediated PDGF signaling and neurovascular coupling in stroke. J Thromb Haemost 2009;7(suppl 1):155–158.
3. Schielke GP, Lawrence DA. Plasminogen activators in ischemic stroke. In: Behrendt N, ed. Matrix proteases in health and disease. Weinheim, Germany: KGaA, Wiley-VCH Verlag GmbH & Co., 2012;ch6. p. 127–156.
4. Hastings GA, Coleman TA, Haudenschild CC, et al. Neuroserpin, a brain-associated inhibitor of tissue plasminogen activator is localized primarily in neurons. Implications for the regulation of motor learning and neuronal survival. J Biol Chem 1997;272:33062–33067.
5. Osterwalder T, Cinelli P, Baici A, et al. The axonally secreted serine proteinase inhibitor, neuroserpin, inhibits plasminogen activators and plasmin but not thrombin. J Biol Chem 1998;273:2312–2321.
6. Osterwalder T, Contartese J, Stoeckli ET, et al. Neuroserpin, an axonally secreted serine protease inhibitor. EMBO J 1996;15:2944–2953.
7. Schrimpf SP, Bleiker AJ, Brecevic L, et al. Human neuroserpin (PI12): cDNA cloning and chromosomal localization to 3q26. Genomics 1997;40:55–62.
8. Takao M, Benson MD, Murrell JR, et al. Neuroserpin mutation S52R causes neuroserpin accumulation in neurons and is associated with progressive myoclonus epilepsy. J Neuropathol Exp Neurol 2000;59:1070–1086.
9. Coutelier M, Andries S, Ghariani S, et al. Neuroserpin mutation causes electrical status epilepticus of slow-wave sleep. Neurology 2008;71:64–66.
10. Davis RL, Shrimpton AE, Holohan PD, et al. Familial dementia caused by polymerization of mutant neuroserpin. Nature 1999;401:376–379.
11. Davis RL, Shrimpton AE, Carrell RW, et al. Association between conformational mutations in neuroserpin and onset and severity of dementia. Lancet 2002;359:2242–2247.
12. Belorgey D, Sharp LK, Crowther DC, et al. Neuroserpin Portland (Ser52Arg) is trapped as an inactive intermediate that rapidly forms polymers: implications for the epilepsy seen in the dementia FENIB. Eur J Biochem 2004;271:3360–3367.
13. Qian Z, Gilbert ME, Colicos MA, et al. Tissue-plasminogen activator is induced as an immediate-early gene during seizure, kindling and long-term potentiation. Nature 1993;361:453–457.
14. Tsirka SE, Gualandris A, Amaral DG, Strickland S. Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator. Nature 1995;377:340–344.
15. Yepes M, Sandkvist M, Coleman TA, et al. Regulation of seizure spreading by neuroserpin and tissue-type plasminogen activator is plasminogen-independent. J Clin Invest 2002;109:1571–1578.
16. Tan ML, Ng A, Pandher PS, et al. Tissue plasminogen activator does not alter development of acquired epilepsy. Epilepsia 2012;53:1998–2004.
17. Ishigami S, Sandkvist M, Tsui F, et al. Identification of a novel targeting sequence for regulated secretion in the serine protease inhibitor neuroserpin. Biochem J 2007;402:25–34.
18. Gualandris A, Jones TE, Strickland S, Tsirka SE. Membrane depolarization induces calcium-dependent secretion of tissue plasminogen activator. J Neurosci 1996;16:2220–2225.
19. Hassanien SH, Awadalla MM, Saad AA, Aziz NAA. Tissue plasminogen activator in children with idiopathic and intractable epilepsies. J Pediatr Neurol 2010;8:193–197.
20. Pawlak R, Melchor JP, Matys T, et al. Ethanol-withdrawal seizures are controlled by tissue plasminogen activator via modulation of NR2B-containing NMDA receptors. Proc Natl Acad Sci USA 2005;102:443–448.
21. Nicole O, Docagne F, Ali C, et al. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med 2001;7:59–64.
22. Yepes M, Sandkvist M, Moore EG, et al. Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J Clin Invest 2003;112:1533–1540.
23. Yepes M, Lawrence DA. New functions for an old enzyme: nonhemostatic roles for tissue-type plasminogen activator in the central nervous system. Exp Biol Med 2004;229:1097–1104.
24. Fredriksson L, Li H, Fieber C, et al. Tissue plasminogen activator is a potent activator of PDGF-CC. EMBO J 2004;23:3793–3802.
25. Su EJ, Fredriksson L, Geyer M, et al. Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat Med 2008;14:731–737.
26. Stanimirovic DB, Friedman A. Pathophysiology of the neurovascular unit: disease cause or consequence? J Cereb Blood Flow Metab 2012;32:1207–1221.
27. Marchi N, Tierney W, Alexopoulos AV, et al. The etiological role of blood-brain barrier dysfunction in seizure disorders. Cardiovasc Psychiatry Neurol 2011; vol. 2011, Article ID 482415, 9 pages. doi: 10.1155/2011/482415
28. Stafstrom CE. Mechanisms of action of antiepileptic drugs: the search for synergy. Curr Opin Neurol 2010;23:157–163.
29. Schuele SU, Luders HO. Intractable epilepsy: management and therapeutic alternatives. Lancet Neurol 2008;7:514–524.
30. Janigro D. Does leakage of the blood-brain barrier mediate epileptogenesis?. Epilepsy Curr 2007;7:105–107.
31. Marchi N, Angelov L, Masaryk T, et al. Seizure-promoting effect of blood-brain barrier disruption. Epilepsia 2007;48:732–742.
32. Friedman A, Kaufer D, Heinemann U. Blood-brain barrier breakdown-inducing astrocytic transformation: novel targets for the prevention of epilepsy. Epilepsy Res 2009;85:142–149.
33. Walther H, Lambert JDC, Jones RSG, et al. Epileptiform activity in combined slices of the hippocampus, subiculum and entorhinal cortex during perfusion with low magnesium medium. Neurosci Lett 1986;69:156–161.
34. Moore SJ, Throesch BT, Murphy GG. Of mice and intrinsic excitability: genetic background affects the size of the postburst afterhyperpolarization in CA1 pyramidal neurons. J Neurophysiol 2011;106:1570–1580.
35. Singer BH, Gamelli AE, Fuller CL, et al. Compensatory network changes in the dentate gyrus restore long-term potentiation following ablation of neurogenesis in young-adult mice. Proc Natl Acad Sci USA 2011;108:5437–5442.
36. Teesalu T, Kulla A, Simisker A, et al. Tissue plasminogen activator and neuroserpin are widely expressed in the human central nervous system. Thromb Haemost 2004;92:358–368.
37. Yamamoto M, Sawaya R, Mohanam S, et al. Expression and cellular localization of messenger RNA for plasminogen activator inhibitor type 1 in human astrocytomas in vivo. Cancer Res 1994;54:3329–3332.
38. Michalak Z, Sano T, Engel T, et al. Spatio-temporally restricted blood-brain barrier disruption after intra-amygdala kainic acid-induced status epilepticus in mice. Epilepsy Res 2013;103:167–179.
39. Huber D, Cramer EM, Kaufmann JE, et al. Tissue-type plasminogen activator (t-PA) is stored in Weibel-Palade bodies in human endothelial cells both in vitro and in vivo. Blood 2002;99:3637–3645.
40. Salles FJ, Strickland S. Localization and regulation of the tissue plasminogen activator-plasmin system in the hippocampus. J Neurosci 2002;22:2125–2134.
41. Cauli B, Tong XK, Rancillac A, et al. Cortical GABA interneurons in neurovascular coupling: relays for subcortical vasoactive pathways. J Neurosci 2004;24:8940–8949.
42. Hamel E. Perivascular nerves and the regulation of cerebrovascular tone. J Appl Physiol 2006;100:1059–1064.
43. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci 2004;5:347–360.
44. Tallquist MD, Soriano P. Cell autonomous requirement for PDGFRalpha in populations of cranial and cardiac neural crest cells. Development 2003;130:507–518.
45. Zhuo L, Theis M, Alvarez-Maya I, et al. hGFAP-cre transgenic mice for manipulation of glial and neuronal function in vivo. Genesis 2001;31:85–94.
46. Brown RC, Egleton RD, Davis TP. Mannitol opening of the blood-brain barrier: regional variation in the permeability of sucrose, but not 86Rb+ or albumin. Brain Res 2004;1014:221–227.
47. Wakai A, McCabe A, Roberts I, Schierhout G. Mannitol for acute traumatic brain injury. Cochrane Database Syst Rev 2013;8:CD001049.
48. Davis RL, Holohan PD, Shrimpton AE, et al. Familial encephalopathy with neuroserpin inclusion bodies. Am J Pathol 1999;155:1901–1913.
49. Gourfinkel-An I, Duyckaerts C, Camuzat A, et al. Clinical and neuropathologic study of a French family with a mutation in the neuroserpin gene. Neurology 2007;69:79–83.
50. Hagen MC, Murrell JR, Delisle MB, et al. Encephalopathy with neuroserpin inclusion bodies presenting as progressive myoclonus epilepsy and associated with a novel mutation in the Proteinase Inhibitor 12 gene. Brain Pathol 2011;21:575–582.
51. Tian GF, Azmi H, Takano T, et al. An astrocytic basis of epilepsy. Nat Med 2005;11:973–981.
52. Ivens S, Kaufer D, Flores LP, et al. TGF-beta receptor-mediated albumin uptake into astrocytes is involved in neocortical epileptogenesis. Brain 2007;130:535–547.
53. Shlosberg D, Benifla M, Kaufer D, Friedman A. Blood-brain barrier breakdown as a therapeutic target in traumatic brain injury. Nat Rev Neurol 2010;6:393–403.
54. Riggio S. Traumatic brain injury and its neurobehavioral sequelae. Psychiatr Clin North Am 2010;33:807–819.
55. Alberti A. Seizures. Front Neurol Neurosci 2012;30:30–33.
56. Myint PK, Staufenberg EF, Sabanathan K. Post-stroke seizure and post-stroke epilepsy. Postgrad Med J 2006;82:568–572.
57. Merali Z, Leung J, Mikulis D, et al. Longitudinal assessment of imatinib's effect on the blood-brain barrier after ischemia/reperfusion injury with permeability MRI. Transl Stroke Res 2015;6:39–49.
58. Ma Q, Huang B, Khatibi N, et al. PDGFR-alpha inhibition preserves blood-brain barrier after intracerebral hemorrhage. Ann Neurol 2011;70:920–931.
59. Leybaert L, Cabooter L, Braet K. Calcium signal communication between glial and vascular brain cells. Acta Neurol Belg 2004;104:51–56.
60. Park L, Gallo EF, Anrather J, et al. Key role of tissue plasminogen activator in neurovascular coupling. Proc Natl Acad Sci USA 2008;105:1073–1078.
61. An J, Haile WB, Wu F, et al. Tissue-type plasminogen activator mediates neuroglial coupling in the central nervous system. Neuroscience 2014;257:41–48.
62. Wu F, Wu J, Nicholson AD, et al. Tissue-type plasminogen activator regulates the neuronal uptake of glucose in the ischemic brain. J Neurosci 2012;32:9848–9858.
63. Wu F, Nicholson AD, Haile WB, et al. Tissue-type plasminogen activator mediates neuronal detection and adaptation to metabolic stress. J Cereb Blood Flow Metab 2013;33:1761–1769.
64. Trevelyan AJ, Sussillo D, Watson BO, Yuste R. Modular propagation of epileptiform activity: evidence for an inhibitory veto in neocortex. J Neurosci 2006;26:12447–12455.
65. Trevelyan AJ, Sussillo D, Yuste R. Feedforward inhibition contributes to the control of epileptiform propagation speed. J Neurosci 2007;27:3383–3387.
66. Yepes M, Roussel BD, Ali C, Vivien D. Tissue-type plasminogen activator in the ischemic brain: more than a thrombolytic. Trends Neurosci 2009;32:48–55.
67. Li J, Yu L, Gu X, et al. Tissue plasminogen activator regulates Purkinje neuron development and survival. Proc Natl Acad Sci USA 2013;110:E2410–E2419.
68. Seeds NW, Basham ME, Ferguson JE. Absence of tissue plasminogen activator gene or activity impairs mouse cerebellar motor learning. J Neurosci 2003;23:7368–7375.
69. Minor K, Phillips J, Seeds NW. Tissue plasminogen activator promotes axonal outgrowth on CNS myelin after conditioned injury. J Neurochem 2009;109:706–715.
70. Seeds NW, Siconolfi LB, Haffke SP. Neuronal extracellular proteases facilitate cell migration, axonal growth, and pathfinding. Cell Tissue Res 1997;290:367–370.
71. Tsirka SE, Rogove AD, Strickland S. Neuronal cell death and tPA. Nature 1996;384:123–124.
72. Tsirka SE, Rogove AD, Bugge TH, et al. An extracellular proteolytic cascade promotes neuronal degeneration in the mouse hippocampus. J Neurosci 1997;17:543–552.
73. Rogove AD, Tsirka SE. Neurotoxic responses by microglia elicited by excitotoxic injury in the mouse hippocampus. Curr Biol 1998;8:19–25.
74. Parcq J, Bertrand T, Montagne A, et al. Unveiling an exceptional zymogen: the single-chain form of tPA is a selective activator of NMDA receptor-dependent signaling and neurotoxicity. Cell Death Differ 2012;19:1983–1991.
75. Miranda E, Lomas DA. Neuroserpin: a serpin to think about. Cell Mol Life Sci 2006;63:709–722.
76. Zhang C, Wang X, Wang Y, et al. Risk factors for post-stroke seizures: a systematic review and meta-analysis. Epilepsy Res 2014;108:1806–1816.